TG Therapeutics, Inc.

TGTX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$23,383$12,672-$198,335-$348,101
Dep. & Amort.$280$423$515$494
Deferred Tax$0$0$0$517
Stock-Based Comp.$42,541$37,933$19,185$61,274
Change in WC-$109,297-$84,659-$1,647-$12,216
Other Non-Cash$2,576$2,218$4,112$2,398
Operating Cash Flow-$40,517-$31,413-$176,170-$295,634
Investing Activities
PP&E Inv.-$45$0-$14-$401
Net Acquisitions$0$0$19,999-$69
Inv. Purchases-$311,891-$146,880-$107,274-$55,531
Inv. Sales/Matur.$310,900$96,229$87,275$55,600
Other Inv. Act.$0$0-$19,999$69
Investing Cash Flow-$1,036-$50,651-$20,013-$332
Financing Activities
Debt Repay.$137,262$25,000-$975$40,000
Stock Issued$0$46,296$584$2,219
Stock Repurch.-$8,760$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$25$1,409$0-$800
Financing Cash Flow$128,527$72,705-$391$41,419
Forex Effect$0$0$0$0
Net Chg. in Cash$86,974-$9,359-$196,574-$254,547
Supplemental Information
Beg. Cash$94,218$103,577$300,151$554,698
End Cash$181,192$94,218$103,577$300,151
Free Cash Flow-$40,562-$31,413-$176,184-$296,035